OptMed, Inc., founded as a privately held company, focuses on developing, manufacturing, and commercializing medical devices, specifically skin protectants and surgical adhesives. Their core mission is to enhance surgical outcomes and patient care through innovative adhesive technologies. Utilizing a proprietary platform chemistry based on methylidene malonate, OptMed offers products like the BlauProtect® brand of skin protectants, which have received CE markings and are available in the EU, and the SpectrumEX™ Topical Skin Adhesive.
Notable figures associated with OptMed include leading scientists and medical professionals who contribute to the company's R&D efforts. The company has attracted significant investment from venture capital firms specializing in healthcare innovations. Key achievements include obtaining CE markings for their BlauProtect® products and expanding their market presence in the EU. OptMed's impact lies in improving surgical procedures and patient outcomes globally through their cutting-edge adhesive technologies.
